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Introduction
Chlamydia is now recognized as a common source of
respiratory infection; most humans will have an infec-
tion at least once during their lifetime,1 and the infec-
tion is often subclinical or mildly self-limited. The
genus Chlamydophila includes Chlamydophila pneu-
moniae (C. pneumoniae), Chlamydophila psittaci and
Chlamydophila trachomatis; C. pneumoniae has been
identified as an important cause of pneumonia since
the 1980s. Several studies have reported C. pneumoniae
involvement in 6–20% of community-acquired pneu-
monia;2,3 the clinical picture of Chlamydia pneumonia
is usually mild and prolonged. However, the course
of illness, even in the elderly, is not essentially different
from the course of other bacterial pneumonia infec-
tions, and severe life-threatening disease with respira-
tory failure requiring intensive care unit (ICU) support
has seldom been reported.4,5 Although most severe
Chlamydia pneumonia patients are elderly or have
comorbid disease, several case reports of healthy adults
with acute hypoxemic respiratory failure due to infec-
tion with C. pneumoniae can be found.6–9 Studies have
shown that 35–47% of C. pneumoniae pneumonia is
mixed with other pathogens, the most common being
Streptococcus pneumoniae.10–12 Thus, the clinical presen-
tation may be severe and sometimes resemble bacterial
pneumonia. C. pneumoniae pneumonia-associated
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Risk factors of Chlamydia pneumonia associated with ARDS
acute respiratory distress syndrome (ARDS) is rare,
but the outcome is usually fatal. An early recognition
of the risk of developing ARDS could reduce this high
mortality. Therefore, this study was designed to identify
the risk factors for hospitalized C. pneumoniae pneu-
monia patients developing ARDS, and to describe the
outcomes.
Methods
Patients
Between January 1995 and January 2005, patients over
18 years of age who were diagnosed with C. pneumo-
niae pneumonia while hospitalized in Taipei Veterans
General Hospital, a tertiary medical center, were ret-
rospectively analyzed. The diagnosis of C. pneumoniae
pneumonia was based on clinical symptoms and signs
(cough, fever, dyspnea, abnormal breathing sounds),
radiographic findings showing new pulmonary infil-
tration, and microimmunofluorescence (MIF) test
criteria suggested by the Centers for Disease Control
and Prevention (CDC)13 and evaluated by a College
of American Pathologists-accredited laboratory. Using
these criteria, 21 patients with a discharge diagnosis
of C. pneumoniae pneumonia were re-evaluated, and
only 5 patients who fulfilled the criteria of acute infec-
tion (IgM ≥ 1:16 or a 4-fold increase in IgG) and 6
patients who fulfilled the criteria of possible acute
infection (IgG ≥ 1:512) were included in this study.
The study was approved by the institutional review
board of Taipei Veterans General Hospital.
Patient evaluation
In addition to the MIF test for C. pneumoniae, all
patients underwent clinical and radiographic evaluation.
The following variables were recorded: age, sex and
underlying disease. Within 24 hours after admission,
vital signs, such as systolic blood pressure, body tem-
perature, pulse rate and respiratory rate, laboratory
findings, chest radiographic features (unilateral or
bilateral), and numbers of lobes involved (involve-
ment of more than 2 lobes was defined as multilobar
involvement) were recorded, as well as blood culture
and sputum culture data collected within 2 days 
after admission, serologic tests for Mycoplasma and
Legionella pneumonia, initial empiric antibiotics used,
hospital days and survival status. The severity of illness
was evaluated by the Acute Physiology and Chronic
Health Evaluation (APACHE) II score and CURB-65
score (a 6-point score, 1 point each for confusion,
urea > 7 mmol/L, respiratory rate ≥ 30/min, systolic
blood pressure < 90 mmHg or diastolic blood pressure
≤ 60 mmHg, age ≥ 65 years)14 within 24 hours after
admission. Patients developing acute respiratory fail-
ure with ARDS, defined by the ATS/ERS criteria,15
comprised the ARDS group, and the others, the non-
ARDS group. Arterial blood gas data, time to pro-
gression, and ICU admission data were also collected.
The clinical characteristics of the ARDS group and
the non-ARDS group were analyzed and compared.
Serologic test
C. pneumoniae-specific serum IgG and IgM levels
were determined by the MIF method using a com-
mercial kit (SeroFIA-Chlamydia; Savyon Diagnostics,
Ashdod, Israel). Sera were tested for IgG in serial 
2-fold dilutions from 1:8 to the endpoint, and in a
single dilution of 1:20 for IgM. Primary infection with
Chlamydia pneumoniae was defined as IgM ≥ 1:16,
and re-infection was defined as IgG ≥ 1:512, or a 4-fold
increase in IgG without elevation of IgM.16 Also, all
patients had negative serologic tests for Mycoplasma
and Legionella pneumonia.
Statistical analysis
We compared categorical data using χ2 statistics or
Fisher’s exact test, and continuous data using the
Mann–Whitney U test. We assumed statistical signifi-
cance for p < 0.05.
Results
Eleven patients met the CDC diagnostic criteria for
acute or possibly acute C. pneumoniae infection, and
ARDS developed in 6 of 11 patients, usually within 7
days of admission; only 1 patient developed ARDS on
the 14th day. Five of 6 patients needed to be trans-
ferred to the ICU, and all of these patients died
(Table 1). All ARDS patients had higher initial
APACHE II (Figure 1) and CURB-65 scores (Table 1).
Mixed infection with other pathogens was found in 
3 of 11 patients, and they all developed ARDS within
7 days (Table 1) and died, although there was no 
statistical significance when compared to the others
(p = 0.121). When analyzing the clinical data gathered
within 24 hours of admission in relation to ARDS,
the APACHE II score, CURB-65 score, systolic
blood pressure, serum creatine, and lactate dehydro-
genase all showed significant differences between the
ARDS and non-ARDS groups (Table 2). In a further
exploration of the risk factors between the 2 groups,
we discovered that those aged ≥ 75 years, with under-
lying disease (including congestive heart failure, dia-
betes or liver cirrhosis), an APACHE II score ≥ 12,
a CURB-65 score ≥2, abnormal white blood cell count
(WBC > 12,000/mm3 or < 4,000/mm3), serum crea-
tine > 1.4 mg/dL, and bilateral or multilobar radio-
logic involvement showed a statistically significant
difference in the development of ARDS, while no dif-
ference could be found in sex, smoking history, 
C-reactive protein, primary infection or re-infection
with C. pneumoniae, and initial treatment with appro-
priate antibiotics, including macrolide or quinolone
(Table 3), within 24 hours.
Discussion
C. pneumoniae pneumonia is generally considered to
be a mildly infectious disease; however, severe mani-
festations evolving into ARDS, with high mortality,
especially in the elderly, have been reported occasion-
ally.17 In another community-acquired pneumonia
study, 6 of 25 C. pneumoniae pneumonia patients had
respiratory failure; 5 were > 60 years old and had other
underlying diseases.5 In our study, 6 of 11 C. pneumo-
niae pneumonia patients developed ARDS, with 5
deaths; 5 of 11 C. pneumoniae pneumonia patients
without ARDS all survived. The higher mortality may
be attributed to the high prevalence of ARDS (6/11)
and the relatively older population compared with
other studies,4,10 with a mean age of 68 years in our
study. Since the MIF test had some false-negative
results, and tissue culture or polymerase chain reaction
assay of respiratory secretions could not be performed
in this retrospective study, and given the fact that our
hospital is a tertiary referral center, many mild but
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Figure 1. Acute Physiology and Chronic Health Evaluation
(APACHE) II scores in the acute respiratory distress syndrome
(ARDS) and non-ARDS groups of hospitalized Chlamydophila
pneumoniae pneumonia patients (p < 0.01).
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serologically negative suspicious cases may have been
treated as atypical pneumonia and underestimated in
this study, causing a higher prevalence of ARDS.
C. pneumoniae has been reported to cause pneumo-
nia frequently in association with other respiratory
pathogens, and mixed infection was noted in 35–47% of
cases.10,18 Three of 11 (27%) patients in this study had
mixed infection with other pathogens found by sputum
cultures collected within 2 days of admission, and all of
these patients died. Gram-negative bacilli and oxacillin-
resistant Staphylococcus were the main pathogens, and all
of the patients had been admitted to other hospitals in
the 3 months prior to this episode. In a previous
study,10 C. pneumoniae as a single etiology often mani-
fested mild illness, however, mixed infection might have
been the predisposing factor for ARDS and mortality.
Our study found mixed infection in 50% of the ARDS
group of patients, and none in the non-ARDS group,
although there was no statistical significance.
The CURB-65 score is a simple tool for risk assess-
ment of community-acquired pneumonia and has sig-
nificant correlation with 30-day mortality, need for
mechanical ventilation, and patients’ rate of hospital
admission for community-acquired pneumonia.19 All
non-ARDS group patients in this study had lower
CURB-65 scores (< 2); in addition, the risk of devel-
oping ARDS was significant when CURB-65 score ≥ 2.
It seemed that the CURB-65 score also predicted the
outcome of C. pneumoniae pneumonia.
In primary C. pneumoniae infection, the MIF IgM
antibody is first detectable about 3 weeks after disease
onset, then the IgG antibody appears 6–8 weeks later.
However, in re-infection, the IgM antibody may not
appear, and the IgG antibody titer quickly rises within
2 weeks.16 Pneumonia due to Chlamydia re-infection
can be more or less severe than that due to primary
infection.18 In this study, we found that primary or re-
infection was not related to the development of ARDS.
Cigarette smoking has been considered to be a
risk factor for C. pneumoniae infection; however, this
was not seen in our study, as in others.5 A specific
finding is that the initiation of appropriate antibiotics
with quinolone or macrolide did not prevent further
ARDS development.
The limitations of this study include the small
sample size from a single tertiary medical center, and
being a retrospective review, some important factors
worthy of exploration could not be explored. We did
find that ARDS was a strong poor prognostic factor
for Chlamydia pneumonia, and that if precipitating
factors could be recognized earlier, the higher mor-
tality of C. pneumoniae associated with ARDS might
be diminished. However, these clinical significances
require exploration in further prospective studies.
Table 2. Clinical data within 24 hours of admission of the acute respiratory distress syndrome (ARDS) group and the non-ARDS
group*
ARDS (n = 6) Non-ARDS (n = 5) Total (n = 11) p
Age (yr) 74.00 ± 17.74 59.25 ± 16.09 67.55 ± 17.05 0.18
CURB-65 score 2.00 ± 0.63 0.40 ± 0.55 1.27 ± 1.01 < 0.01†
APACHE II score 19.33 ± 7.76 5.80 ± 3.11 13.18 ± 9.16 < 0.01†
Physical examination
SBP (mmHg) 96.17 ± 17.20 134.25 ± 15.20 111.40 ± 25.06 < 0.01†
Temperature (°C) 37.93 ± 1.15 37.85 ± 0.62 37.90 ± 0.93 0.79
RR (/min) 22.33 ± 5.61 21.75 ± 2.06 22.10 ± 4.36 0.93
Pulse (/min) 127.17 ± 21.32 112.25 ± 8.85 121.20 ± 18.38 0.13
Laboratory data
WBC (/mm3) 12,733.33 ± 7,033.54 8,625.00 ± 2,786.13 11,090 ± 5,879.80 0.33
Hemoglobin (mg/dL) 11.00 ± 1.49 12.63 ± 2.13 11.65 ± 1.86 0.08
Platelets (/mm) 188,500 ± 86,586 189,250 ± 151,033 188,800 ± 108,484 1.00
CRP (mg/dL) 13.23 ± 10.09 6.60 ± 4.90 10.58 ± 8.73 0.33
Creatine (mg/dL) 2.15 ± 1.08 0.85 ± 0.17 1.63 ± 1.05 0.02†
Total bilirubin (mg/dL) 1.57 ± 1.19 0.85 ± 0.45 1.28 ± 0.99 0.35
Albumin (g/dL) 2.83 ± 0.55 3.60 ± 0.37 3.14 ± 0.61 0.07
CK (U/L) 179.00 ± 146.00 53.25 ± 34.30 128.70 ± 128.27 0.07
LDH (U/L) 539.33 ± 201.28 215.25 ± 89.71 409.70 ± 230.65 0.02†
*Data are presented as mean ± standard deviation; †p < 0.05. APACHE = Acute Physiology and Chronic Health Evaluation; SBP = systolic blood pressure; RR =
respiratory rate; WBC = white blood cell count; CRP = C-reactive protein; CK = creatine kinase; LDH = lactate dehydrogenase.
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In conclusion, C. pneumoniae patients associated
with ARDS have higher mortality and ICU admission
rates. The risk factors for developing ARDS when a
patient is hospitalized may include an older age and
higher initial APACHE II and CURB-65 scores,
underlying comorbid disease, severe leukocytosis or
leukopenia, impaired renal function and bilateral or
multilobar involvement.
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